Literature DB >> 15192786

The molecular pathogenesis of cholangiocarcinoma.

Eric P Berthiaume1, Jack Wands.   

Abstract

Cholangiocarcinoma is rising in clinical importance because of increasing incidence, poor prognosis, and suboptimal response to therapy. Recent investigations into the underlying molecular mechanisms involved in cholangiocarcinogenesis and tumor growth have contributed greatly to our understanding of this disease. To review this topic, we discuss the molecular mechanisms in sections reflecting the unique features that allow cancer cells to develop and maintain a growth advantage. Through a better understanding of these mechanisms, improved and more specific diagnostic, therapeutic, and preventative strategies may be developed and hopefully improve the outcome of this devastating disease.

Entities:  

Mesh:

Year:  2004        PMID: 15192786     DOI: 10.1055/s-2004-828890

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  28 in total

Review 1.  Cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Ghulam Abbas; Keith D Lindor
Journal:  J Gastrointest Cancer       Date:  2009-08-25

2.  Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.

Authors:  Dongdong Lu; Chang Han; Tong Wu
Journal:  Gastroenterology       Date:  2011-02-24       Impact factor: 22.682

Review 3.  Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.

Authors:  Halim Charbel; Firas H Al-Kawas
Journal:  Curr Gastroenterol Rep       Date:  2011-04

4.  Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.

Authors:  Naoki Oishi; Mia R Kumar; Stephanie Roessler; Junfang Ji; Marshonna Forgues; Anuradha Budhu; Xuelian Zhao; Jesper B Andersen; Qing-Hai Ye; Hu-Liang Jia; Lun-Xiu Qin; Taro Yamashita; Hyun Goo Woo; Yoon Jun Kim; Shuichi Kaneko; Zhao-You Tang; Snorri S Thorgeirsson; Xin Wei Wang
Journal:  Hepatology       Date:  2012-08-22       Impact factor: 17.425

5.  Molecular mechanisms of cholangiocarcinoma.

Authors:  Giammarco Fava
Journal:  World J Gastrointest Pathophysiol       Date:  2010-04-15

6.  Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma.

Authors:  Mohamed S Hashim Abdalla; Simon D Taylor-Robinson; Amar W Sharif; Horace R T Williams; Mary M E Crossey; Gamal A Badra; Andrew V Thillainayagam; Devinder S Bansi; Howard C Thomas; Imam A Waked; Shahid A Khan
Journal:  HPB (Oxford)       Date:  2011-03-22       Impact factor: 3.647

Review 7.  The significance of genetics for cholangiocarcinoma development.

Authors:  Luca Maroni; Irene Pierantonelli; Jesus M Banales; Antonio Benedetti; Marco Marzioni
Journal:  Ann Transl Med       Date:  2013-10

8.  Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M. and Lillian Stratton Basic Research Single-Topic Conference.

Authors:  Alphonse E Sirica; Michael H Nathanson; Gregory J Gores; Nicholas F Larusso
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

Review 9.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

10.  miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF).

Authors:  Jinqiang Zhang; Chang Han; Hanqing Zhu; Kyoungsub Song; Tong Wu
Journal:  Am J Pathol       Date:  2013-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.